Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.
Keeling
A A
AA
Department of Immunology, University of Birmingham, UK.
Vaughan
A T
AT
Beaney
R P
RP
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism; D007942:Leukemia, Experimental / Q000378:metabolism / Q000532:radiotherapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004369:Pentetic Acid / Q000494:pharmacology; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*
D009942:Organometallic Compounds; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D015021:Yttrium Radioisotopes; C061699:yttrium ethylenediaminetetra(methylenephosphonic acid); D004369:Pentetic Acid